SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Fears that Democratic election gains could bring tighter AI and data-center rules or delay buildouts are weighing on Nvidia and semiconductor stocks. Traders are divided over whether the policy risk is serious or overblown, with some selling amid concern about AI spending and others treating the decline as a buying opportunity.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros strong quarterly results and higher outlook were met with a sharp selloff, prompting traders to debate whether margin pressure, customer concentration and cash-flow concerns outweigh the growth story. Some also blame election-related fears about AI data-center expansion, while bullish traders argue the market reaction ignores the companys results.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Concerns that Democratic election gains could slow or tighten oversight of U.S. AI data-center expansion have driven a sharp selloff in Micron and other chip stocks. Traders are divided between calling the move an overreaction given memory demand and Microns fundamentals, and fearing slower AI investment or a broader semiconductor repricing.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is caught in a selloff across AI infrastructure and neocloud stocks as traders worry that Democratic election gains could bring tighter data-center rules and slow the buildout. Bears also cite financing, execution, and valuation risks, while bulls argue Nebiuss global footprint and limited exposure to Texas make the reaction excessive and could leave its capacity more valuable.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk is being swept up in a sharp selloff across memory and AI-related stocks as traders worry that Democratic election gains could bring tighter oversight and slow U.S. data-center construction. The community is divided between expecting further declines and arguing that strong memory demand and company fundamentals make the pullback an overreaction.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

A sharp semiconductor selloff, even as broader markets rose, has traders debating whether election-related concerns about data-center restrictions will slow AI infrastructure spending; some see the pullback as an overreaction and buying opportunity, while others warn of a deeper AI-capex repricing.

Root, Inc. is a technology insurance company, which engages in the provision of insurance services. It offers mobile telematics and technology platforms to segment individual risk based on complex behavioral data and customer experience to make pricing decisions and grow businesses. It provides insurance products and services in the United States. The company was founded by Alexander E. Timm and Daniel Manges in February 2015 and is headquartered in Columbus, OH.

Root Inc - Ordinary Shares - Class A

Root Inc

Roots Q3 earnings report and share repurchases are driving discussion, with traders highlighting continued profitability while debating a revenue miss and weak policy growth. Bullish posters see the results and buybacks as support for the shares, while skeptics question whether growth can recover.

e.l.f. Beauty, Inc. is a holding company, which engages in the provision of inclusive, accessible, clean, vegan and cruelty free cosmetics and skin care products. The company focuses on the e-commerce, national retailers and international business channels. Its brands include elf, elf skin, naturium, well people, and keys soulcare. The company was founded in 2004 and is headquartered in Oakland, CA.

e.l.f. Beauty Inc

e.l.f. Beautys strong fiscal Q2 results and raised full-year outlook are driving attention, with traders highlighting sales growth, margin expansion and Rhodes international rollout. Many are bullish on the beat and guidance, while others question whether the news is already priced in and are taking profits after the stocks rally.

OFFICIAL TRUMP (TRUMP) is a cryptocurrency and operates on the Solana platform. OFFICIAL TRUMP has a current supply of 999,998,803.281286 with 281,866,738.952788 in circulation. The last known price of OFFICIAL TRUMP is 1.25123586 USD and is down -18.81 over the last 24 hours. It is currently trading on 744 active market(s) with $499,293,542.16 traded over the last 24 hours. More information can be found at https://gettrumpmemes.com/.

Trump For President

TRUMP is drawing attention amid a sharp selloff and reports of fresh lows, with traders largely criticizing the Trump-branded meme coin as having little intrinsic utility and accusing insiders of benefiting while holders lose money. Some community members defend it as a high-risk, tradable meme asset or are buying the dip, while talk that political scrutiny could add pressure remains speculation.

X-Energy, Inc. engages in the development of advanced small modular nuclear reactors and fuel technology for clean energy generation. Its solutions include Xe-100 and TRISO-X. The company was founded by Kam Ghaffarian and Eben Mulder in 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-Energy Inc

A sharp selloff and repeated tests of new lows dominate discussion, with traders blaming post-IPO selling, a bearish analyst downgrade, and weakness across nuclear stocks; some also speculate about lockup-related supply, though that explanation is disputed. Long-term bulls point to X-energys Amazon-backed reactor plans and rising power demand, while skeptics emphasize that commercialization and meaningful revenue remain years away.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (NASDAQ: UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Unicycive Therapeutics, Inc. (Unicycive or the Company) (NASDAQ: UNCY) and reminds investors of the November 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class...

UNCY Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Unicycive Therapeutics Securities Lawsuit - Contact SueWallSt

UNCY Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Unicycive Therapeutics Securities Lawsuit - Contact SueWallSt UNCY Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Unicycive Therapeutics Securities Lawsuit - Contact SueWallStPR...

UNCY Shareholder Alert: November 2, 2026 Lead Plaintiff Deadline in Unicycive Therapeutics, Inc. Securities Class Action - Contact Levi & Korsinsky

UNCY Shareholder Alert: November 2, 2026 Lead Plaintiff Deadline in Unicycive Therapeutics, Inc. Securities Class Action - Contact Levi & Korsinsky UNCY Shareholder Alert: November 2, 2026 Lead Plaintiff Deadline in Unicycive Therapeutics, Inc. Securities Class Action - Contact Levi & KorsinskyPR...

UNCY Deadline: Rosen Law Firm Urges Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Stockholders to Contact the Firm for Information About Their Rights

Rosen Law Firm, a global investor rights law firm, reminds investors about a class action on behalf of purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026. Unicycive describes itself as a clinical-stage biotechnology company...

Unicycive Deadline: UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit

Unicycive Deadline: UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit Unicycive Deadline: UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud LawsuitPR NewswireNEW YORK, Oct. 24, 2026 NEW YORK, Oct. 24, 2026 /PRNewswire...

What's Next for Unicycive Therapeutics, Inc. Shareholders After 39.1% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff Deadline

What's Next for Unicycive Therapeutics, Inc. Shareholders After 39.1% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff Deadline What's Next for Unicycive Therapeutics, Inc. Shareholders After 39.1% Stock Drop? Glancy Prongay Wolke & Rotter LLP...

What Does Unicycive Therapeutics, Inc.'s 39.1% Stock Drop Mean for Investors? The Law Offices of Howard G. Smith Outlines Securities Fraud Class Action Lead Plaintiff Deadline

What Does Unicycive Therapeutics, Inc.'s 39.1% Stock Drop Mean for Investors? The Law Offices of Howard G. Smith Outlines Securities Fraud Class Action Lead Plaintiff Deadline What Does Unicycive Therapeutics, Inc.'s 39.1% Stock Drop Mean for Investors? The Law Offices of Howard G. Smith Outlines...

UNCY UPCOMING DEADLINE: SueWallSt Alerts Unicycive Therapeutics, Inc. Stockholders of Securities Class Action - Contact the Firm

UNCY UPCOMING DEADLINE: SueWallSt Alerts Unicycive Therapeutics, Inc. Stockholders of Securities Class Action - Contact the Firm UNCY UPCOMING DEADLINE: SueWallSt Alerts Unicycive Therapeutics, Inc. Stockholders of Securities Class Action - Contact the FirmPR NewswireNEW YORK, Oct. 22, 2026 A...

Robbins LLP Reminds UNCY Investors of the Pending Lead Plaintiff Deadline in the Unicycive Therapeutics, Inc. Securities Class Action Lawsuit

Robbins LLP Reminds UNCY Investors of the Pending Lead Plaintiff Deadline in the Unicycive Therapeutics, Inc. Securities Class Action Lawsuit Robbins LLP Reminds UNCY Investors of the Pending Lead Plaintiff Deadline in the Unicycive Therapeutics, Inc. Securities Class Action LawsuitPR NewswireSAN...

What Should Unicycive Therapeutics, Inc. Investors Know After 39.1% Stock Drop? The Law Offices of Frank R. Cruz Outlines Securities Fraud Class Action Lead Plaintiff Deadline

What Should Unicycive Therapeutics, Inc. Investors Know After 39.1% Stock Drop? The Law Offices of Frank R. Cruz Outlines Securities Fraud Class Action Lead Plaintiff Deadline What Should Unicycive Therapeutics, Inc. Investors Know After 39.1% Stock Drop? The Law Offices of Frank R. Cruz Outlines...

This account has been verified as an official UNCY representative.

Verified Account

Sara Frederick

Unicycive Therapeutics, Inc. is a biotechnology company, which engages in developing novel treatments for kidney diseases. The firm investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.

Unicycive Therapeutics Inc

UNCY Stock Clocks Worst Day In A Year — Analysts Keep Buy Ratings Despite ‘5-12 Month Delay’ In Drug Approval

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>The company was seeking approval for the drug to treat hyperphosphatemia in patients with chronic kidney disease on dialysis.&nbsp;</li><li>Both B. Riley and H.C. Wainwright kept their ‘Buy’ ratings on the stock following the FDA rejection.&nbsp;</li><li>Unicycive said that it is in active engagement with the FDA.</li></ul>Shares of Unicycive Therapeutics Inc. (UNCY) clocked their worst day in over a year on Tuesday after the company announced that the U.S. Food and Drug Administration has again refused to approve its drug oxylanthanum carbonate (OLC), sparking mixed reactions from Wall Street.UNCY stock closed down 39% and fell a further 9% after-hours.<h2 class="st-heading-2">Analysts Maintain 'Buy' Ratings Despite Delays</h2>B. Riley maintained its ‘Buy’ rating and $22 price target on the stock. The firm noted that the FDA’s rejection relates solely to third-party manufacturing issues rather than clinical safety or efficacy, with no additional data requests. While delayed, overall commercial opportunity and cash runway remain unchanged, the analyst stated.H.C. Wainwright, meanwhile, lowered its price target to $15 from $22 while keeping a ‘Buy’ rating. The firm sees potential launch delays of 5-12 months, but also emphasized that the FDA raised no new concerns on clinical efficacy or safety.<h2 class="st-heading-2">FDA Issues UNCY Second Rejection</h2>Unicycive said on Tuesday that the FDA refused approval for OLC to treat hyperphosphatemia in patients with chronic kidney disease on dialysis, citing the same third-party manufacturing deficiencies identified in the prior rejection letter issued in June 2025.“The FDA has not raised any concerns regarding clinical efficacy or safety data, and no additional data was requested from Unicycive,” the company said. It added that the application had been resubmitted based on continued progress by the vendor in resolving deficiencies identified last year. The agency has not yet inspected the third-party vendor as part of the resubmitted application review, it noted.“We remain confident in the efficacy and safety of OLC. We are in active and ongoing discussion with the FDA regarding label and packaging, and we are optimistic that there will be a successful inspection of the third-party manufacturing vendor and that we will be able to expeditiously resubmit the NDA,” CEO Shalabh Gupta said.<h2 class="st-heading-2">How Did UNCY Retail Traders React?</h2>On Stocktwits, retail sentiment around UNCY stock stayed in the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.A Stocktwits user voiced optimism for the drug getting approved eventually in a few months.<stembedurl>https://www.stocktwits.com/flyinghollaender/message/657965891</stembedurl>Another user voiced frustration with the company’s management.<stembedurl>https://www.stocktwits.com/Neurogirl/message/657948575</stembedurl>A third user said that the market “overreacted.”<stembedurl>https://www.stocktwits.com/Logmart939/message/657937778</stembedurl><a href="https://stocktwits.com/symbol/UNCY">UNCY stock</a> has lost 19% year–date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/lcid-stock-rises-video-of-uber-ceo-in-gravity-robotaxi-fuels-retail-interest-in-lucid-waymo/cZ1QrjAR70V">LCID Stock Rises — Why A Video Of Uber CEO Inside Gravity Robotaxi Is Fueling Retail Interest In Lucid And Waymo</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In the wake of OWL's redemption restrictions, Senator Elizabeth Warren called for tighter oversight of private credit.

Unicycive Therapeutics said on Tuesday that the U.S. Food and Drug Administration has again refused to approve its drug oxylanthanum carbonate. 

Current Price	$3.75
Prev Close	$3.59
Open	$3.67
Dividend Yield	0.00%
50-Day Moving Average	$4.43
Beta	0.88
Avg. Volume	1.09M
PE Ratio	-2.35

52-Week High	$8.74
52-Week Low	$3.33
Market Capitalization	$100M
EPS (Annual)	-$1.67
Price to Book	1.96
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

UNCY Fundamentals